[Lymphocyte subpopulations in maintenance hemodialysis patients receiving recombinant human erythropoietin].
The effect of recombinant human erythropoietin (rHuEPO) on the lymphocyte subpopulations of maintenance hemodialysis patients has been studied. Peripheral lymphocyte counts, lymphocyte subpopulations (Two color analysis) and PHA-induced proliferative response were measured before and after rHuEPO administration during 8 months in 22 stable hemodialysis patients (mean age 52 years, mean duration of dialysis 48 months). We could find a significant increase in the proportions of CD4+ Leu8- cells, HLA-DR+ cells, CD8+ HLA-DR+ cells, CD14+ HLA-DR+ cells and CD4+ Leu8-/CD8+ CD11b+ cells ratios after rHuEPO therapy. In addition, a significant decrease in the proportions of CD16+ CD57- cells and CD20+ cells could be found after rHuEPO therapy. These results suggest that rHuEPO administration to stable hemodialysis patients induces increases in lymphocytes categorized into helper subset groups and in activated T lymphocytes.
Kaneko
Y
Y
Department of Urology, Nara Medical University, Japan.
Motomiya
Y
Y
Arai
K
K
Kagebayashi
Y
Y
Okada
H
H
Sasaki
K
K
Yoneda
T
T
Yoshida
K
K
Ozono
S
S
Hirao
Y
Y
D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000032:analysis; D002908:Chronic Disease; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D005921:Glomerulonephritis / Q000276:immunology* / Q000628:therapy; D006801:Humans; D008213:Lymphocyte Activation; D016131:Lymphocyte Subsets; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis
D015703:Antigens, CD; D011994:Recombinant Proteins; D004921:Erythropoietin